Declaration of interests: Virginia Rojo Guerra

Opinion/decision on a Paediatric investigation plan (PIP): Fintepla, fenfluramine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0390/2022

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000229605

Highlight report - Combination Products Operational Group (COMBO) - In Vitro Diagnostics stream - June 2026

Organisation chart: Information Management

Human medicines European public assessment report (EPAR): Elaprase, idursulfase, Date of authorisation: 08/01/2007, Revision: 27, Status: Authorised

EMA/PE/0000235658

EMA/PE/0000240018

Opinion/decision on a Paediatric investigation plan (PIP): Jyseleca, filgotinib maleate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: EMA/PE/0000232302

Opinion/decision on a Paediatric investigation plan (PIP): Voxzogo, vosoritide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000224087